摘要
目的探讨基质金属蛋白酶组织抑制剂-1(TIMP-1)在高血压肾硬化发生及发展过程中作用。方法利用酶联免疫吸附试验(ELISA)双抗体夹心法,分别对20例原发性高血压、20例高血压肾硬化、20例高血压肾硬化尿毒症病人外周血TIMP-1含量进行检测。结果高血压肾硬化尿毒症组、高血压肾硬化组血清中TIMP-1的含量均高于原发性高血压组,差异有显著性(F=208.97,q=30.87、22.96,P<0.01);高血压肾硬化尿毒症组血清中TIMP-1的含量高于高血压肾硬化组,差异有显著性(q=7.95,P<0.01)。结论TIMP-1含量增高在高血压性肾小球硬化和肾间质纤维化的发生及发展过程中起着重要作用。
Objective To study the correlation of tissue inhibitors of metalloproteinase-1 （TIMP-1） and hypertensive nephrosclerosis and to investigate the role of TIMP-1 in the development of the disease. Methods The TIMP1 levels were determined by enzyme/inked immunoadsorbent assay （ELISA） double-ant/body sandwich method in patients with essential hypertension （EH, 20 cases）, hypertensive nephrosclerosis （HN, 20）, and hypertensive nephrosclerosis complicated by uremia （HNU, 20）. Results The content of serum TIMP-1 in patients with HNU and HN was significantly higher than that of the EH （F= 208.97;q=30. 87,22.96;P〈0.01）. The content of serum TIMP-1 in patients with HNU was significanty higher than that of the HN （q= 7.95, P〈0.01 ）. Conclusion The increase of TIMP-1 plays an important role in the occurrence and development of hypertensive nephrosclerosis and renal interstitial fibrosis.
出处
《齐鲁医学杂志》
2006年第3期233-234,共2页
Medical Journal of Qilu
